Samsung Biologics to participate in BioJapan 2025 to discuss collaborative opportunities
Samsung Biologics will participate in BioJapan 2025, Asia’s largest biopharmaceutical partnering event, held in Yokohama, Japan from October 8 to 10.
Samsung Biologics, which has participated for three consecutive years since 2023, will operate its first exclusive booth this year, taking a proactive approach to securing business opportunities and expanding market share with top global pharmaceutical companies. At Booth D-105, the company will highlight its one-stop, end-to-end capabilities supported by advanced facilities, focusing on antibody-drug conjugate services, world-leading capacity, and dedicated development platforms.
On the first day on October 8, James Choi, Executive Vice President and Head of Sales Support, and Kevin Sharp, Executive Vice President and Head of Sales & Operation, will each present sessions on ‘Strategic Outsourcing for Supply Chain Resilience’ and ‘Integrating Biologics Development and Manufacturing for Diverse Modalities’.
Samsung Biologics opened a sales office in Tokyo earlier this year to actively engage with clients in Japan and the broader APAC region.
Samsung Biologics will participate in BioJapan 2025, Asia’s largest biopharmaceutical partnering event, held in Yokohama, Japan from October 8 to 10.
Samsung Biologics, which has participated for three consecutive years since 2023, will operate its first exclusive booth this year, taking a proactive approach to securing business opportunities and expanding market share with top global pharmaceutical companies. At Booth D-105, the company will highlight its one-stop, end-to-end capabilities supported by advanced facilities, focusing on antibody-drug conjugate services, world-leading capacity, and dedicated development platforms.
On the first day on October 8, James Choi, Executive Vice President and Head of Sales Support, and Kevin Sharp, Executive Vice President and Head of Sales & Operation, will each present sessions on ‘Strategic Outsourcing for Supply Chain Resilience’ and ‘Integrating Biologics Development and Manufacturing for Diverse Modalities’.
Samsung Biologics opened a sales office in Tokyo earlier this year to actively engage with clients in Japan and the broader APAC region.
Share article
Related Content